Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.
about
The Relationship between NALP3 and Autoinflammatory SyndromesTreating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesLighting the fires within: the cell biology of autoinflammatory diseasesBeyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescenceWorking the endless puzzle of hereditary autoinflammatory disorders.IL-1 blockade in autoinflammatory syndromes.An update on autoinflammatory diseasesFirst report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).Targeting the inflammasome in rheumatic diseases.Autoinflammatory syndromesMolecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.New tricks from an old dog: mitochondrial redox signaling in cellular inflammation.Biological treatments: new weapons in the management of monogenic autoinflammatory disordersMonogenic autoinflammatory diseases: concept and clinical manifestations.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.Recurrent fevers in children: TRAPS for young players.Monogenic autoinflammatory diseases.Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).Recommendations for the management of autoinflammatory diseases.Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review.A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner.A Comprehensive Overview of the Hereditary Periodic Fever Syndromes.Canakinumab for the treatment of TNF-receptor associated periodic syndrome.Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital.Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens.An Update on the Use of Immunomodulators in Primary Immunodeficiencies.An Up-to-date Approach to a Patient with a Suspected Autoinflammatory Disease.Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.Autoinflammatory Diseases with Periodic Fevers.Modified regimen of etanercept for tumor necrosis factor receptor associated periodic syndrome (TRAPS) like illness.Tumor necrosis factor-associated periodic syndrome in adults.Biological therapies in monogenic autoinflammatory diseases: long-term efficacy and safety.A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra.Inositol-Requiring Enzyme 1-Mediated Downregulation of MicroRNA (miR)-146a and miR-155 in Primary Dermal Fibroblasts across Three TNFRSF1A Mutations Results in Hyperresponsiveness to Lipopolysaccharide.
P2860
Q26749025-FAFB0432-979A-4E1C-BC55-EF2E7636BBC1Q26799747-78BE5FAB-57CD-4303-BD32-D5A3C4B1F1E1Q26827163-01785D45-1721-43FB-8FA7-DC93F146F441Q27011650-DFCA6F1A-6A69-4847-9EE1-87A11CD21E17Q33357128-08E6368B-4BAB-49C7-A277-3DDB69166E58Q34262561-1C312FCE-6FA4-432A-84D4-1567F16AE908Q34380526-0D73BCB4-C289-4776-B39D-52A2A92D0AECQ34997023-A8980D0C-A71A-4B18-BD17-28D3BF18B5BDQ35804717-70B1C328-5CC9-449F-88C6-B28F561D6AFEQ35810569-6F69021C-B31F-4C12-B650-E25D78C87240Q36041225-9572A91B-E602-403C-84D3-2448EB5E0DF2Q36834142-29E4B1E3-8B9A-40D2-A1C2-4034337060F8Q37077564-EC81EF01-D783-44C0-902F-B1EA470B7858Q37162157-BA034929-4E81-456C-A1F7-6EC61F3D92C0Q37270409-5FFBCE70-CD82-45E2-B760-E6EBC7193E31Q37466515-EBEB0F43-D512-4484-989E-D44E3955D679Q37604504-0F52D45F-E12C-4B23-9F56-D41A2655284EQ37703762-CEDAD859-EB41-4989-B2C4-DB7A02D3396EQ38211947-DACD590B-89A7-46EC-9CAE-F749D3D5DC69Q38220758-164FB06C-B671-4CE3-9F58-3740C59DC990Q38517828-2C7970A7-B32E-4EB9-86E5-B70D82EC118CQ38537504-77C8052E-8760-4945-937D-85DAAF61CE10Q38635412-74CAD618-8F5F-41E7-B09C-5F16E88B74C4Q38746358-48BECE99-8EDC-4E49-883D-B1F64151BC8AQ38773387-D4791B41-0AB6-460E-B693-EE819C179942Q38805718-5D1C94D4-222E-4C87-BBBA-AF670496C7DBQ38814103-0DE2F694-A1C3-4018-B064-3B762704ECA1Q38826765-19F88453-9AC0-4F17-A943-AF4E061DF4D2Q38843398-A7E3A806-AD07-489F-A5D6-6805BAE41CC0Q39016299-881C82BD-3D27-4508-AB28-EF023E0AF89CQ39126636-4219F16A-C447-456F-AB6B-E2A111DD331CQ39301708-24D980A2-E8A4-4CE7-A68C-C1C0715E0398Q39325689-5D1091EC-33EC-4249-BA0F-CA5A1D71EBDEQ39384980-50DC3744-BE4B-4524-A068-27F845D48A68Q40217036-AFF5D37F-BF46-4F53-9381-4176CC14856FQ41929105-B66A1CAD-07E0-4A53-A00D-ADD1607A2AF6Q46104569-B0CED537-8CF5-4D9E-88EC-22E6333A76A4Q47133706-2E70EFF1-1D22-4C45-8959-72ACE278C959Q50152542-AB590B30-06A6-4226-A6F6-4B2E23CD64D2
P2860
Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy of etanercept in the ...... -label, dose-escalation study.
@en
Efficacy of etanercept in the ...... -label, dose-escalation study.
@nl
type
label
Efficacy of etanercept in the ...... -label, dose-escalation study.
@en
Efficacy of etanercept in the ...... -label, dose-escalation study.
@nl
prefLabel
Efficacy of etanercept in the ...... -label, dose-escalation study.
@en
Efficacy of etanercept in the ...... -label, dose-escalation study.
@nl
P2093
P2860
P356
P1476
Efficacy of etanercept in the ...... -label, dose-escalation study.
@en
P2093
Ariel C Bulua
Cheryl H Yarboro
Daniel L Kastner
David Y He
Douglas B Mogul
Harjot Singh
Ivona Aksentijevich
Keith M Hull
Larry R Muenz
Michael M Ward
P2860
P304
P356
10.1002/ART.33416
P577
2012-03-01T00:00:00Z